Introduction
Since its regulatory approval for testicular and ovarian cancers in the USA in 1978, cisplatin developed into an indispensable and effective anticancer agent.
1 Its cytotoxic properties stem from direct DNA binding which induces a series of signal transduction-pathways of which some lead to cell death. 2, 3, 4 However, early observations of acquired drug-resistance and severe side effects triggered the development of further derivatives of this compound's class that culminated in the approval of carboplatin and oxaliplatin. 5, 6 The pharmacological activity of platinum agents was found to be affected by the ligands coordinated at the metal center and this insight was exploited as a basis for the rational design of next-generation anticancer agents.
In this context, organometallic compounds are promising candidates for future therapeutic schemes. By definition, organometallic complexes are characterized by at least one metalcarbon bond. Given that a carbon atom offers four bonding orbitals and three hybridization types, organometallic complexes yield an abundant number of stereochemically and geometrically diverse scaffolds that allow fine-tuning of their biological and physiochemical
properties. Moreover, the metal-carbon bonds are kinetically inert and display high stability, essential to control metallodrugs speciation in aqueous environment. Organometallic complexes are well-established in homogenous catalysis. In particular, they are widely applied in the activation of small molecules, olefin polymerization and in different organic transformations such as carbonylation reactions and carbon-carbon bond formations. 7 Beyond that, organometallic scaffolds attract increasing interest in drug discovery because they offer a large unexplored chemical area with respect to biological and medicinal applications. 8 Typical representatives of ligands used for metal-carbon complexation include carbonyls, alkynyls, cyclopentadienyls, arenes, cyclometalated and N-heterocyclic carbenes (NHCs) as illustrated in Fig. 1 . 9 As an example, Ferroquine is a ferrocene-containing antimalarial agent that currently undergoes phase II clinical trials and shows promise to overcome chloroquine resistance. 10 A cytostatic cobalt(0) complex (Co-AcS, AcS = acetylsalicylic acid) containing carbonyls and an alkyne as ligands has been shown to inhibit COX-2 via different binding modes than AcS alone, and the ruthenium(II) complex [Ru(η 6 -arene)(PTA)Cl2] (RAPTA-C; PTA = 1,3,5-triaza-7-phosphaadamantane) displayed strong antimetastatic activity in ovarian and colorectal xenografts. 11, 12 Consequently, it is now generally accepted that even simple modifications of organometallic scaffolds dictate target preferences.
Fig. 1 -Structures of organometallic compounds used for medicinal purposes.
Within this framework, N-heterocyclic carbenes (NHCs) are of particular interest among the ligand scaffolds available for novel bioactive organometallic complexes. They consist of a neutral heterocycle with a two-electron donating carbenic carbon between two nitrogen atoms.
Usually, NHCs are singlet carbenes conferring strong σ-donor properties as a ligand and low tendency to dimerize. The synthesis of the first NHC metal complex dates back to 1968, and since the first reports on free stable NHCs and their applicability as ligands in the early 1990ies 13 NHC popularity increased strongly, while even gradually supplanting the use of conventional tertiary phosphines as σ-donors. Notably, NHC carbenes form strong bonds with metals yielding organometallic complexes of high chemical and thermal stability, and they are also easily derivatised and even immobilized on carrier materials. 14 Recent developments in inorganic drug discovery of metal NHCs, focus on coinage (Au, Ag, Cu) and platinum-group metals (Pt, Ru, Pd, Os, Ir) and their structure-activity relationships as well as biological targets are being elucidated. [15] [16] [17] [18] [19] 20 The biological modes of action of antiproliferative NHC complexes have been investigated for several of these metal ions and led to the identification of different potential molecular targets. 12, [15] [16] [17] [19] [20] [21] [22] [23] Among these mechanisms, cell cycle arrest and mitochondrial dysfunctions (e.g. ROS production, changes in mitochondrial membrane potential, cytochrome c release and caspase activation) may be responsible for triggering apoptosis in cancer cells and this is on the one hand caused by the interaction of such metal-based drug candidates with proteins. 24, 25 For example, selected gold(I)
NHC complexes are assumed to induce apoptosis by inhibition of thioredoxin reductase (TrxR). 26 The latter is a seleno-enzyme that is overexpressed in several cancer cells and plays an important regulatory role in the cellular redox-balance. 21, 26 Other enzymatic targets of anticancer metal NHC-based complexes are glutathione reductase (GR), deubiquitinase (DUB), cyclooxygenase (COX) and cathepsin B, respectively. 24 Readers are directed to further references to cover the implication and modes of actions of metal NHCs as antimicrobial drugs. 23 Interestingly, the cyclophane NHC-based Au(I) complex comprising an ortho-substituted xylylene scaffold (Figure 1 ) in addition to be a cytotoxic agent, is luminescent, most likely as a result of short Au(I) … Au(I) contacts (< 3 Å) induced by the cyclophane ligand framework. 27 This distance can be modulated as a function of the bridging unit within the bis-NHC ligand.
Luminescence properties of metal complexes are particularly attractive for monitoring their intracellular distribution, e.g. for targeting specific cells/organs. As an example, Ag(I) and Au(I) NHC complexes bearing a fluorescent anthracenyl ligand were examined for cytotoxicity in normal and tumor cells. 28 Fluorescence microscopy experiments showed that both compounds enter cells, and are particularly efficient in penetrating tumor cells where they reach the nuclear compartment.
More recently, acridine wingtip NHC-based Au(I) complexes showed strong antiproliferative activity and fluorescence based on IL transitions, and were found to be localized primarily in lysosomes of A549 cells by fluorescence microscopy, and in the nuclei to a lower extent.
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From recent studies, it emerged that NHC-derived organometallic anticancer agents show the potential to target specific DNA secondary structures and often in a purely non-covalent mode of binding. Selectivity for such DNA secondary structures is expected to increase target selectivity, while reducing off-target activity and, therefore, reducing side effects. In this perspective, we aim at categorizing DNA secondary structures as targets for organometallic NHC complexes as anticancer agents, and at highlighting the promising therapeutic gains from altering such structures. Similarly, fluorescent metal NHC probes targeting DNA secondary structures might be useful for imaging purposes to uncover their implications of in tumor biology. Thus, the different modes of binding will be discussed in the following chapters, as well as possible future developments in the field.
Metal NHC Complexes Targeting DNA Secondary Structures
DNA is a peculiar molecule of high complexity that carries the genomic code. Two complementary strands are associated in a helix that is condensed into chromosomes by wrapping the double helix around histone octamers as nucleosome core particles (Figure 2 ).
However, loosening this tightly packed arrangement is required for transcription. The corresponding euchromatin can be further unfolded and forms specific structural motifs of DNA architecture. Duplex DNA, mismatched DNA and replication forks represent double-stranded motifs, while promotor G-quadruplexes (G4s), telomeric G4s and i-motifs represent intrastrand structures ( Figure 2 ). Figure 3 depicts the adducts of different DNA secondary structures with metallodrugs featuring different binding modes including (A) coordination, (B) insertion and (C) stacking, which will be discussed in this review in more detail.
Direct coordinative binding to the DNA double strand was the initial target engagement of inorganic anticancer agents, especially platinum agents. Similarly, the use of coordinationbased compounds to recognize DNA in a supramolecular fashion is undisputed. 32 However, it has only more recently emerged that DNA is a structurally heterogeneous molecule that can adopt defined secondary structures, which in turn may be targeted by small molecules. Here, the aim is to provide a rationale for selectively targeting secondary DNA structures and to show that organometallic NHC complexes are especially suited as scaffolds for targeting these structures. (9-methylcaffein-8-ylidene)2] + to a telomeric G-quadruplex via noncovalent interactions. The pdb accession codes are given and the structures were generated using NGL.
Targeting Duplex DNA
The induce the nucleophilic attack on the phosphate backbone of DNA. 38 The resulting cleavage generates 5'-OPO3 and 3'-OH fragments, which are similar to those obtained from naturally occurring nucleases (Scheme 1A). 37, 39 Moreover, certain metal complexes react with oxygen or hydrogen peroxide to form reactive oxygen species (ROS) and damage DNA in an oxidative manner 36,37 generating Fenton-type reactions. 40 Highly reactive hydroxyl radicals ( · OH) formed in the presence of Fe(II), for example, can add to double bonds of DNA bases or abstract hydrogen atoms from the methyl group of thymine and the ribose building block, respectively. 41 Scheme 1B illustrates DNA cleavage after H-abstraction at the sugar moiety.
Scheme 1 -Postulated mechanisms of (A) hydrolytic cleavage of DNA and (B) oxidative cleavage at ribose moiety. . 42 Upon treatment with the gold compounds, the DNA extracted from U373-GB glioblastoma cells was highly fragmented as monitored by gel electrophoresis assays. This effect was attributed to an elevated DNA binding affinity of the benzyl-functionalization of the carbene ligands.
A Ru(II) NHC complex (2) demonstrated a strong antiproliferative effect towards human colon carcinoma (HCT-15) and epidermoid cancer (Hep2) cells. 43 In gel electrophoresis assays, distinct dose-dependent DNA interactions were observed, which induced DNA cleavage, as well as DNA aggregation upon increasing the metal concentration up to 100 µM. It was suggested that 2 would intercalate into DNA and subsequently catalyze DNA cleavage.
McAlpine and coworkers showed that the incorporation of an imidazole-type NHC ligand to a rhodium(I) cyclooctadiene (COD) fragment (3) generated a chemical nuclease with remarkable antiproliferative activity against HCT116 colon cancer cells (IC50: 3 µM). 44 Mechanistic investigations underlined DNA interactions to be causative for the antiproliferative effect. Gel electrophoresis assays revealed that this compound is capable of binding to supercoiled plasmid DNA and trigger a transformation to the nicked form. Furthermore, the restriction endonuclease BamHI was not able to digest the DNA when incubated with 3, indicating a conformational change of the DNA upon interaction with the metallo-NHC compound. In fact, the conformational change induced by this organo-rhodium(I) compound was suggested to lead to DNA replication arrests as observed in BrdU incorporation assays with HCT116 cells, which also impaired cellular migration.
Due to their redox properties, copper compounds are well-known for their DNA cleaving activities, in particular by inducing oxidative damage. 45 Consequently, copper(I) NHC complexes bearing either one (4, Figure 4 ) or two 1,3-bis(2,4,6-trimethylphenyl)imidzolin-2-ylidene carbene ligand moieties were investigated for their interaction with duplex DNA. 46 In Interestingly, the same experiment conducted in the presence of a singlet oxygen (NaN3) or hydroxyl radical (DMSO) scavenger quenched this behavior. Therefore, it was concluded that 4 was DNA damaging by generating ROS only under normoxic conditions. 
Direct coordination
Alkylating agents bind irreversibly to DNA and induce conformational changes such as bending or unwinding, thus hampering vital replication and transcription processes. 3, 47 The earliest examples of direct interactions between metallodrugs and DNA stem from platinum(II)
anticancer compounds that coordinatively bind to DNA upon ligand exchange as revealed by X-ray crystallography ( Figure 3A) . 48 For example, activated cisplatin coordinates favourably to the nucleophilic N7 position of purine bases, especially guanine. Monometallic intrastrand, and to a lesser extent interstrand crosslinks, can form upon hydrolysis of both metal-halido bonds. 3, 6, 49 Concerning the case of experimental gold-based anticancer compounds, their mode of action is governed by the inhibition of key proteins/enzymes and/or possible oxidative damage, leading to cell death; 21, 48 while direct coordination of gold compounds to duplex DNA has been thought to be of scarce relevance. Especially those compounds bearing at least one labile ligand have been shown to be susceptible to interact with cellular nucleophiles on biomolecules, including cysteine-containing proteins (e.g. albumin or metallothionein) and thiol/selenol-based enzymes (e.g. TrxR).
Nevertheless, Gust and coworkers demonstrated that gold(I) NHC complexes 5a and 5b ( Figure   5 ) -with ligands derived from pharmacologically active 4,5-diarylimidazole bearing -OCH3
and -F substitutions -present important cytotoxic properties and moderate coordinative binding to duplex DNA. 50 In fact, measurements of the binding efficiency of the complexes to salmon testes DNA showed increased binding for 5a and 5b (2.03 pmol/µg and 1.03 pmol/µg, respectively) compared to Et3PAuCl (0.11 pmol/µg), but which was still weaker than cisplatin Furthermore, novel mechanistic behaviors were reported for a polymeric formulation of platinum(II) NHC fragments attached to a bidentate polyethylenimine ligand, a known transfection agent (7, Figure 5 ). 52 Notably, the complex is much more effective than cisplatin and oxaliplatin against HCT-116 (human colorectal adenocarcinoma) cells. Evaluation of the subcellular distribution of 7 demonstrated that only 16% of the total intracellular platinum accumulated in the nucleus while 20% was found in mitochondria. Comparatively, 57% of oxaliplatin located in the nucleus whereas only 3.5% were found in mitochondria. The dual targeting of nuclei and mitochondria by 7 has been hypothesized to contribute to the promising anticancer effects in cell that exhibit resistance towards common platinum drugs. Moreover, in vivo experiments confirmed that 7 is more effective than oxaliplatin in reducing tumor growth. 53 In fact, an almost two-fold higher tumor volume inhibition (80%) with respect to oxaliplatin was reached in a xenograft mouse models bearing HCT-116 tumor, upon treatment with 10 mg/kg of 7 once every 48 h. Notably, no side effects were observed with compound 7 whereas the treatment of oxaliplatin induced hemorrhagic events.
Recently, Schobert and coworkers performed extensive investigations on the effect of cis-and trans-configured platinum(II) NHC complexes on biological activities including DNA interactions. 53, 54 In vitro screening of a series of 1,3-dibenzylimidazolylidene Pt(II) complexes with different leaving groups trans to it (8a-c, Figure 5 ) showed that the antiproliferative activity strongly depends on the nature and position of this ligand (PPh3, 2-picoline, Cl and NHC, respectively). Interestingly, it was demonstrated that the higher the number of PPh3, which might sterically restrict the contact with DNA or the hydrolysis of the leaving chloride, ligands, the lower the ability and rate to irreversibly bind to double-stranded CT DNA. Finally, the authors suggested that the trend of cell growth inhibition in this series was a result of the ability of the compounds to cause DNA aggregation. For example, the bis-carbene 8d did not cause aggregation using light scattering experiments, while the mono-carbene 8c induced the condensation of 50% of the total amount of DNA at a concentration of 0.51 μM. 54 These results, together with those of the EMSA and EtdBr studies, support the hypothesis that 8c might interact with DNA predominantly via noncovalent interactions, facilitated by its positive charge.
Thereupon, cis-oriented bis-NHC platinum(II) complexes (9a-b, Figure 5 ) were analyzed for their anticancer activities towards different cell lines. 54 Overall, both complexes showed remarkable antiproliferative activity but the "delocalized lipophilic cationic" (DLC) 9b was A family of half-sandwich ruthenium(II)(arene) compounds featuring NHC ligands (e.g.
exemplified by 10, Figure 5 ) showed weak antiproliferative effects against cancer cells and ruthenation of salmon testes DNA of 15-50%, which was lower compared to cisplatin. 55 Later on, the same authors then showed the covalent binding potential of a rhodium(I) COD complex (11) with a similar ligand to duplex DNA. 56 In contrast to the half-sandwich ruthenium NHCs, 11 showed potent antiproliferative activity against MCF-7 human breast adenocarcinoma (IC50 ca. 0.6 µM) and cisplatin-resistant HT-29 colon carcinoma (IC50 ca. 0.9 µM) cell lines.
Moreover, treatment of salmon testes DNA with 11 showed that 72% of the rhodium was bound to DNA after 4 h incubation. However, the compound metallated albumin to a similar extent (67% after 2 h). Further investigations demonstrated the potential to induce apoptosis-inducing changes of mitochondrial membrane potential in Nalm-6 leukemia cells.
Intercalation
Intercalation denotes the non-covalent stacking interaction of planar (heterocyclic) aromatic moieties with adjacent base pairs in duplex DNA. As a result, the double helix structure is affected and undergoes conformational changes involving lengthening, stiffening, and unwinding, respectively, which cause similar therapeutic effects compared to covalent DNA binding, i.e. inhibiting replication and transcription. 37 Intercalating agents such as doxorubicin and anthracyclines in general remain important and widely applied anticancer therapeutics. 32 Moreover, chloroquine completed phase III clinical trials for the treatment of glioblastoma multiform and underlines current clinical developments in this field. 57 Apart from organic small molecules, intercalating agents of various metals have been reported over the last years (e.g.
Zn, Pt, Rh or Ru). 58 Typical metallointercalators contain cyclometalated and N-donor ligated aromatic ring systems, e.g. HCNN (6-phenyl-2,2'-bipyridine), phenanthroline or terpyridine, and exhibit favourably square-planar or octahedral geometries. 59 Despite a structure that is atypical for metallointercalators, Castro and coworkers demonstrated the possibility of non-covalent DNA binding mode for the dinuclear silver mono-Nheterocyclic carbene complex 12 ( Figure 6 ). 60 The complexes displayed antiproliferative activity against six tumor cell lines of different origin, at concentrations below 30 µM. Their interaction with CT DNA was investigated using different methods including absorption spectral titration. Thus, an increase of CT DNA amounts relative to the test compound resulted in a decrease in absorption of 20% with a slight red shift (~ 7 nm), accounting for metal complex/DNA adduct formation. Investigations on the thermal behavior of the DNA in the presence of the silver complex showed a stabilization of the double helix of CT DNA as its melting temperature increased. Consequently, the authors proposed a non-covalent reversible binding behavior of the complex to the DNA. By viscometry it was found that the silver complex induced DNA bending due to non-covalent interaction such as partial intercalation.
Notably, complex 12 did not cause DNA cleavage as demonstrated by gel mobility studies.
Recently, Goite and coworkers examined DNA interactions of a dinuclear silver(I) NHC complexes with rigid pyridine linkers (13, Figure 6 ). 61 The anticancer activities of 13 were first evaluated in vitro, and the compound resulted moderately active. Upon titration of CT DNA, a red shift accompanied by a hypochromic effect at 237 nm (by 22%) and 280 nm (by 21%) was observed in the UV-vis absorption spectra, indicating a binding mode via non-covalent interaction. The viscosity of the DNA/13 mixture is also reduced, probably as a consequence of bending or twisting of the DNA.
Similar to its corresponding silver precursor 12, the dinuclear Au(I) NHC complex 14 was assigned to form non-covalent π-π stacking interactions with duplex DNA as a result of the modified DNA melting profiles. 60 Its cytotoxic activities against MCF-7, PC3, A549, HT-29
and 4T1 cancer cell lines were in similar ranges than for the respective silver complex, but 14 and marker for cancer. 65 The intercalating properties were confirmed by circular dichroism, while the Au(I)-conjugate retained inhibitory properties to TrxR. 66 In vitro studies showed antiproliferative effects against MCF-7 human breast adenocarcinoma and HT-29 colon carcinoma cells. Similar to the intercalating naphtalimide-based ligand, DNA stabilization was also observed upon treatment of CT DNA with the respective gold(I) compounds, expressed as an increase of the thermal denaturation temperature, ΔTm = 11 °C (17a); 6 °C (17b); 4 °C (17c);
6 °C (17d). Furthermore, circular dichroism (CD) spectra showed that 17a behaved similar to the respective imidazolium salts by mainly affecting the base stacking of CT DNA. In contrast, 17b-d additionally distorted the B conformation of DNA as suggested by the increase of the signal intensity at 275 nm. Building on a similar approach, 59 NHC-based complexes exhibiting such a dual binding mode were prepared with ruthenium(II) (18) and rhodium(I) (19) ions (Figure 6 ). 67 Regarding the antiproliferative effects, the rhodium-based compound exhibited low micromolar activities in the breast carcinoma (MCF-7) and colon carcinoma (HT-29) cell lines, while the ruthenium congener (18) 
Mismatch DNA
Misincorporated nucleobases during DNA synthesis that do not match the complementary base pair are termed DNA mismatches. 68 Cells evolved elaborate mechanisms, which sense and repair such defects by excision and rely on the DNA mismatch-repair machinery for this purpose. As a consequence, persistent point-mutations during DNA replication occur only at a part-per-billion frequency in healthy cells. Some colon cancers may show defects in the DNA mismatch-repair machinery and this feature may be valuable as a diagnostic or therapeutic strategy by targeting such mismatches. 69 Some small molecules, including metal-based anticancer agents were shown to interact with mismatched DNA bases. 69, 70 The first report on an intercalating ruthenium metallodrug by Xray diffraction revealed insertion into the site of the A:A mismatch on the oligonucleotide 5'-(dCGGAAATTACCG)2-3' by expulsing both adenines, which then stacked with the ancillary metal-bound phenanthroline ligands ( Figure 3B ). 71 In contrast to platinum anticancer agents binding to duplex DNA via the major groove, this ruthenium compound inserted in the minor groove. In addition to binding to the mismatched site, the metal complex was also able to bind non-covalently to other (abasic) sites, which suggested low selectivity for the mismatch.
Recently, organometallic platinum(II) NHC complexes were reported to probe selectively mismatched DNA over matched DNA. 72 showed that the planar cyclometalated C^N^N ring systems inserted into the mismatch and was able to π-stack with the nucleobases, while the orthogonal backbone engages in secondary hydrophobic interactions with the expulsed nucleobases from the mismatch. Moreover, the homobimetallic species is 2+ charged, which is responsible for additional electrostatic stabilization upon binding to the DNA structure.
Based on these observations, targeting mismatched DNA by organometallic NHC compounds may prove to be a viable strategy to diagnose or treat cancer types that are characterized by a deficiency in the mismatch repair machinery. Highly selective mismatch targeting NHC compounds could be designed to feature ample secondary interactions with the expulsed nucleotides to additionally stabilize the drug-target interaction. 
G-quadruplexes
G-quadruplexes (G4s) are guanosine-rich intrastrand secondary structures of DNA formed by three stacks of guanosine quartets and each quartet assembles in a pseudoplanar arrangement.
The hydrogen bond system is formed by a Watson-Crick edge of one guanine with a Hoogsteen edge of its neighbour, and the stacks are stabilized by two potassium ions ( Figure 8A ). 73 G4s play important roles in cancer progression because of their involvement in telomeric and promoter regions of the genome. 74 Several types of G4 structures have been identified so far by NMR and X-ray diffraction studies, including telomeric repeat DNA consisting of d (TTAGGG) repeats, and promoter regions of oncogenes including MYC, KIT1, KRAS etc. (Figure 8B ).
Fig. 8 -(A) Base-pairing of G-quadruplexes and (B) representative examples including
telomeric G4s (pdb 5CCW) and promoter G4s for MYC (pdb 1XAV) and KIT1 (pdb 2O3M).
Telomeric G4s
G4s were initially characterized as guanine-rich repeats at the single-stranded ends of chromosomes, i.e. the 3'-end in a single strand of about 200 nucleotides. These telomeric repeats protect against DNA degradation by folding into stacks of tightly packed G4s. 75 It was also found that the enzyme telomerase would catalyse the extension of these repeats after cellular duplication events by synthesising d(TTAGGG) telomeric repeats. Overexpression of telomerase is found in many cancer types and supports cellular immortality, which is one of the hallmarks of cancer. 76 It was therefore sought to stabilize G4s in telomeres by small molecules, which in turn would inhibit telomerase activity and thus, show anticancer effects. 75, 77 Recently, a bis-NHC gold(I) complex -[Au(9-methylcaffein-8-ylidene)2] + (22, Figure 9 ) -bearing the natural product caffeine as carbene ligand, has been demonstrated by DNA FRET melting assays to selectively targeting telomeric G4 structures with respect to duplex DNA, while showing selective antiproliferative effects on tumorigenic over healthy cells. 78 The G4
consisted of a 23 nucleotide telomere repeat sequence d(TAGGG(TTAGGG)3. The X-ray structure indicated that the loops of the telomeric G4 do not cover the G-quartets, but extend to the side of the structure in a propeller configuration ( Figure 8B ). This feature allows telomeric G4s to form stacks and the planar 22 was then shown to bind non-covalently between neighboring telomeric G4s. 79 Moreover, the 3,3´-end accommodated one and the 5,5´-end Preliminary structure-activity relationships on this compound family revealed that N9-derivatizations of the xanthine backbone affected the selectivity over duplex DNA. This is exemplified by the methylbenzoate derivative [Au(9-{4-methylbenzoate}caffein-8-ylidene)2] + (23, Figure 9 ). The bulky ligand brakes the planarity of the organometallic compound and results in an orthogonal arrangement of the xanthine ligands. 78 This derivative was equally potent, but less selective for telomeric G4 over duplex DNA compared to the methyl-derivative and suggests that it may interact with telomeric G4 in a different manner. Compound 22 and analogues were evaluated for their toxicity in an ex vivo model that uses tissue slices. 78 Notably, the xanthine-derived compounds were not toxic in healthy tissues, at variance with the benzimidazole-derived analogues.
An additional example of an organometallic NHC-type stabilizer of telomeric G4s was reported by conjugating a trans platinum(II)-NHC moiety to pyridostatin (24, Figure 9 ). 80 The latter is a selective telomeric G4 binder and was expected to direct the platinum(II)-type moiety to specific locations in the nucleus, where the Pt(II) moiety could then bind form to G4s via irreversible coordinative bonds. The compound was shown to cause distinctly different cellular effects compared to cisplatin and displaced the telomere maintenance protein TRF2 from telomeres, but not to such an extent as to induce telomere shortening. Although conclusive structural information has not yet been provided for the interaction of 24 with DNA at a molecular level, the displacement of TRF2 provides evidence that 24 targets telomeric DNA in cellular systems, and represents one of the few examples of a validated target engagement in cells. 
Promoter G4s
In addition to telomeric G4s, it was shown using genome sequencing that approximately 700,000 DNA G4-like sequences, 81 while bioinformatic studies reported around 350,000 sequences with the potential to form G4 structures. 82 Finally, immunoprecipitating G4
structures from cells together with high-throughput sequencing revealed approximately 10,000
G4 structures in human chromatin. 83 It was revealed that these G4 sequences were especially present in non-nucleosomal regions in the genome and that they would enrich in promoter regions of genes. Promoter G4s occur once per promoter region and although small in size, they
show specific architectures according to the arrangement of the loops connecting the guanine stacks, which in principle allow for specific drug targeting, e.g. the G4 sequence in the promoter region of the KIT1 gene is largely conserved and unique in the human genome, and so is presumably its structure. KIT is a proto-oncogene encoding a receptor tyrosine kinase that stimulates proliferation. 84 It has been proposed that formation of the quadruplex structure in these regions may control transcription and as a consequence, the expression of the corresponding oncogenes. Thus, stabilizing G4s by small molecules may be utilized to treat KRAS, KIT1 or c-MYC driven cancers, which are inherently difficult to treat, e.g. lung adenocarcinoma. 85, 86 Promoter G4s are intrastrand structures on duplex DNA and the complementary strand displays a C-rich sequence that may arrange into the so-called i-motif, which is one of the few known cases of systematic base intercalations. 87 This complementary structure is less investigated than the G4 but may prove to be equally useful in a therapeutic or diagnostic context.
Conclusions and Future Directions
The use of metal carbene complexes in various fields beyond catalysis has experienced substantial advances during the last years, including for biomedical applications. Recent proofof-principle studies on organometallic NHC anticancer agents showed that this class of compounds is able to target several canonical and non-canonical DNA secondary structures. In detail, metal NHC complexes were shown to interact with duplex, mismatched and Gquadruplex DNA, while examples of other classes of metal-based anticancer agents exist that inhibit replication forks, 89 by interacting with DNA three-way junctions, 90 spectroscopy and isotope-specific mass spectrometry would allow to follow not only the compounds distribution in cells, but also the structural integrity of the compound, e.g. with regard to ligand exchange reactions. This can even be extended by X-ray absorption near-edge spectroscopy (XANES) to study the composition of the first coordination sphere and the oxidation state of metallodrugs in tissues. 91 Notably, advanced mass spectrometric techniques emerge as promising tools to generate hypotheses on target identification 92 and mechanisms of action in the cellular context.
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Furthermore, recent developments in the DNA targeted field of organometallic NHC anticancer agents show also a trend towards molecular and systems biology approaches in order to elucidate mechanisms of action or effective signal transduction pathways and in situ chemical affinity capture will presumably increase in popularity to validate binding of selected compounds to specific DNA secondary structures in vitro. 86 Similarly, ELISA microarrays may prove useful to globally elucidate signalling events upon drug administration. 94 It is evident that future research in the discovery and development of organometallic NHC compounds has to be directed towards a more rational drug discovery of therapeutic compounds with respect to the targeting of specific DNA secondary structures. Such molecules may be developed also as chemical probes to aid in uncovering the functions of these structures in cancer biology in more detail.
Although the spatial arrangement of the nucleotides in DNA secondary structures may be unique, it remains to be proven whether specific DNA secondary structures can be targeted at all given the complexity of genomic DNA. In particular, targeting of G4s of specific genes would enable a powerful approach for gene silencing at the level of transcription initiation and would be equivalent to a small molecule gene knock-down. Of note, although telomeric and promoter G4s show marked structural differences, it remains challenging to develop selective agents for either type, although coordination metal-based compounds have shown already interesting properties. 95 Similarly, current research efforts are directed towards small molecules that target specific promoter G4s. Moreover, despite intensive research in this area, the actual function of G4s in vivo has not yet been fully understood. Therefore, significant efforts have been devoted to the discovery of specific probes for visualizing and distinguishing G4 structures from other nucleic acid molecules likely to be found in biological environments. 96 In this context, based on the representative examples described in this review, metal NHCs certainly hold great promise.
